MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 38.4% from a year ago
Total equity stood at $254.02M at the end of Q1 FY2026, down 38.4% from a year earlier and down 16.6% from the prior quarter. Over 3 fiscal years it compounded at +64.2% a year.
Context
- Total equity amounted to 63.4% of total assets at the end of Q1 FY2026, down 17.3 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -38.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 304.48M USD
- Year-over-year change
- -32.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 304.48M | -32.8% |
| FY2024 | 2024-12-31 | 453.39M | -11.7% |
| FY2023 | 2023-12-31 | 513.49M | +646.7% |
| FY2022 | 2022-12-31 | 68.77M | +690.5% |
| FY2021 | 2021-12-31 | (11.65M) | — |
Total Equity vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's Mar 2026 total equity of $254.02M is the 5th highest of the 11 companies compared; the peer median is $180.27M.
- Its year-over-year change of -38.4% is the 8th highest of 10, against a peer median of +43.3%.
- Total equity amounts to 63.4% of total assets for MLTX, versus a peer median of 84.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. | Sep 2026 | $1.2B | +145.9% | +124.6% | 97.2% |
| Jun 2026 | $1.17B | +286.7% | +88.5% | 96.6% | |
| Aug 2026 | $968.31M | +160.1% | +21.1% | 81.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $452.16M | -6.8% | — | 80.7% |
| Mar 2026 | $254.02M | -38.4% | +64.2% | 63.4% | |
ZURAZura Bio Limited | Mar 2026 | $216.9M | +43.3% | — | 94.9% |
| Mar 2026 | $143.65M | -0.3% | -19.5% | 72.3% | |
| Jun 2026 | $112.77M | — | — | 87.9% | |
| Mar 2026 | $59.49M | +462.4% | -3.6% | 94.3% | |
| Dec 2025 | $41.98M | -54.5% | -35.6% | 74.9% | |
| Mar 2026 | $12.75M | -62.5% | -47.8% | 3.9% | |
| Peer median (excluding MLTX) | $180.27M | +43.3% | -3.6% | 84.4% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.04M | 39.51M | 451.17M | 180.43M | 334.52M |
| Short-term Investments | 0 | 32.61M | 59.84M | 267.6M | 59.45M |
| Net Receivables | 148.77K | 217.13K | 1.06M | 2.84M | 4.87M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 9.64M | 76.51M | 514.17M | 474.29M | 421.69M |
| Property, Plant & Equipment (Net) | 45.74K | 331.97K | 3.95M | 3.64M | 2.14M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 115.04M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (115.04M) | (0) | 8.42M | 0 | 596K |
| Total Non-current Assets | 45.74K | 331.97K | 12.37M | 3.64M | 2.74M |
| Total Assets | 9.68M | 76.84M | 526.54M | 477.93M | 424.43M |
| Account Payables | 1.23M | 47.48K | 1.46M | 8.68M | 0 |
| Short-term Debt | 15M | 0 | 0 | 0 | 1.23M |
| Tax Payables | 63.92K | 109.83K | 367.98K | 642.11K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.3M | 109.83K | 2.78M | 4.24M | 40.83M |
| Total Current Liabilities | 21.09M | 7.67M | 9.97M | 22.46M | 45.48M |
| Long-term Debt | 0 | 0 | 0 | 0 | 74.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 239.86K | 282.21K | 583.43K | 620.68K | (374K) |
| Total Non-current Liabilities | 239.86K | 411.16K | 3.08M | 2.08M | 74.47M |
| Total Liabilities | 21.33M | 8.08M | 13.05M | 24.54M | 119.95M |
| Common Stock | 38.54K | 5.27K | 6.3K | 6.39K | 7K |
| Retained Earnings | (53.64M) | (80.65M) | (116.66M) | (235.59M) | (462.91M) |
| Accumulated OCI | (168.18K) | 350.95K | 2.36M | 5M | 604K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 19.87M | 17.82M | 6.57M | 0 |
| Total Equity | (11.65M) | 68.77M | 513.49M | 453.39M | 304.48M |
| Total Debt | 15M | 282.58K | 3.7M | 2.83M | 75.71M |
| Net Debt | 6.96M | (39.22M) | (447.47M) | (177.6M) | (258.81M) |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.